Benjamin Charles, DiogenX CEO
May 10, 2023 05:00 AM EDTUpdated 06:25 AM
Financing
Startups

French biotech jumps in­to type 1 di­a­betes space with $30M Se­ries A round

Katherine Lewin

News Reporter

France-based biotech Dio­genX is gear­ing up to jump in­to the race to re­gen­er­ate be­ta cells in di­a­betes pa­tients with the com­ple­tion of a $30 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times